MediWound’s (MDWD) “Buy” Rating Reaffirmed at HC Wainwright

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $25.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 36.76% from the stock’s previous close.

Separately, Craig Hallum assumed coverage on MediWound in a research report on Friday, February 28th. They set a “buy” rating and a $39.00 price target for the company.

MediWound Price Performance

Shares of MDWD stock opened at $18.28 on Thursday. The business has a 50-day moving average of $18.15 and a 200 day moving average of $17.60. The stock has a market capitalization of $197.17 million, a PE ratio of -6.30 and a beta of 0.82. MediWound has a 1-year low of $12.78 and a 1-year high of $24.00.

MediWound (NASDAQ:MDWD) last issued its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.23. The company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the previous year, the firm earned ($0.19) earnings per share. Analysts anticipate that MediWound will post -2.66 EPS for the current year.

Institutional Trading of MediWound

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. R Squared Ltd purchased a new position in MediWound during the fourth quarter valued at $32,000. Russell Investments Group Ltd. raised its position in shares of MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,162 shares during the last quarter. MetLife Investment Management LLC purchased a new position in shares of MediWound in the 3rd quarter worth about $89,000. Bank of America Corp DE boosted its stake in MediWound by 38.0% in the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 2,178 shares in the last quarter. Finally, Rhumbline Advisers grew its position in MediWound by 7.3% during the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock valued at $193,000 after purchasing an additional 739 shares during the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.